Long Non-coding RNA: A Recently Accentuated Molecule in Chemoresistance in Cancer

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2020 Jun 29

PMID 32594276

Citations 27

Authors

Yang Peng

Dihong Tang

Meng Zhao

Hiroaki Kajiyama

Fumitaka Kikkawa

Yutaka Kondo

Affiliations

Soon will be listed here.

Abstract

Chemotherapy is one of the important and effective options for cancer treatment in the past decades. Although the response rate of initial chemotherapy is considerably high in certain types of cancers, such as ovarian cancer and lung cancer, the patients frequently suffer from chemoresistance and recurrence of disease. Recent genome-wide studies have shown that the large number of long non-coding RNAs (lncRNAs) are transcribed from the human genome and involved in many biological processes including carcinogenesis. They aberrantly regulate variety of cell functions, such as cell cycle, apoptosis, autophagy, and metabolisms, which are associated with chemosensitivity. Therefore, understanding the biological and clinical impacts of lncRNAs on tumor behavior and its potential as a predictive biomarker for chemotherapy effectiveness is highly desired. In this review, we classify the major mechanisms of lncRNA-related chemoresistance and provide theoretical evidences for targeting lncRNAs in certain types of cancers that may open up new therapeutic paradigm for cancer treatment.

Citing Articles

Adaptive Significance of Non-coding RNAs: Insights from Cancer Biology.

McDonald J Mol Biol Evol. 2025; 42(1).

PMID: 39761690 PMC: 11725524. DOI: 10.1093/molbev/msae269.

Exosome-mediated Transfer of lncRNA in Liver Associated Diseases; Uncovered Truths.

Saleh R, Hamad H, Najim M, Menon S, Kaur M, Sivaprasad G Cell Biochem Biophys. 2024; .

PMID: 39567423 DOI: 10.1007/s12013-024-01617-x.

Emerging roles of long non-coding RNA FOXP4-AS1 in human cancers: From molecular biology to clinical application.

Yang J Heliyon. 2024; 10(21):e39857.

PMID: 39539976 PMC: 11558633. DOI: 10.1016/j.heliyon.2024.e39857.

[LncRNA MAGI2-AS3 enhances cisplatin sensitivity of non-small cell lung cancer cells by regulating the miR-1269a/PTEN/AKT pathway].

Fan X, Qi Z, Deng Y, Yang Z, Sun L, Li G Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(10):2033-2043.

PMID: 39523104 PMC: 11526470. DOI: 10.12122/j.issn.1673-4254.2024.10.22.

An update on the molecular mechanisms of ZFAS1 as a prognostic, diagnostic, or therapeutic biomarker in cancers.

Mehrab Mohseni M, Zamani H, Momeni M, Shirvani-Farsani Z Discov Oncol. 2024; 15(1):219.

PMID: 38856786 PMC: 11164845. DOI: 10.1007/s12672-024-01078-x.

References

Shewach D, Kuchta R . Introduction to cancer chemotherapeutics. Chem Rev. 2009; 109(7):2859-61. PMC: 4110949. DOI: 10.1021/cr900208x. View

Falzone L, Salomone S, Libra M . Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018; 9:1300. PMC: 6243123. DOI: 10.3389/fphar.2018.01300. View

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N . Drug resistance in cancer: an overview. Cancers (Basel). 2014; 6(3):1769-92. PMC: 4190567. DOI: 10.3390/cancers6031769. View

Swain S . Chemotherapy: updates and new perspectives. Oncologist. 2011; 16 Suppl 1:30-9. DOI: 10.1634/theoncologist.2011-S1-30. View

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

Kondo Y, Shinjo K, Katsushima K . Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci. 2017; 108(10):1927-1933. PMC: 5623749. DOI: 10.1111/cas.13342. View

Schmitt A, Chang H . Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016; 29(4):452-463. PMC: 4831138. DOI: 10.1016/j.ccell.2016.03.010. View

Guttman M, Donaghey J, Carey B, Garber M, Grenier J, Munson G . lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011; 477(7364):295-300. PMC: 3175327. DOI: 10.1038/nature10398. View

Liu K, Gao L, Ma X, Huang J, Chen J, Zeng L . Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020; 19(1):54. PMC: 7066752. DOI: 10.1186/s12943-020-01162-0. View

10.

Tubbs A, Nussenzweig A . Endogenous DNA Damage as a Source of Genomic Instability in Cancer. Cell. 2017; 168(4):644-656. PMC: 6591730. DOI: 10.1016/j.cell.2017.01.002. View

11.

Nagel Z, Kitange G, Gupta S, Joughin B, Chaim I, Mazzucato P . DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res. 2016; 77(1):198-206. PMC: 6100738. DOI: 10.1158/0008-5472.CAN-16-1151. View

12.

Brandsma I, Gent D . Pathway choice in DNA double strand break repair: observations of a balancing act. Genome Integr. 2012; 3(1):9. PMC: 3557175. DOI: 10.1186/2041-9414-3-9. View

13.

Hosoya N, Miyagawa K . Targeting DNA damage response in cancer therapy. Cancer Sci. 2014; 105(4):370-88. PMC: 4317796. DOI: 10.1111/cas.12366. View

14.

Wu P, Cai J, Chen Q, Han B, Meng X, Li Y . Lnc-TALC promotes O-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun. 2019; 10(1):2045. PMC: 6499807. DOI: 10.1038/s41467-019-10025-2. View

15.

Sharma V, Khurana S, Kubben N, Abdelmohsen K, Oberdoerffer P, Gorospe M . A BRCA1-interacting lncRNA regulates homologous recombination. EMBO Rep. 2015; 16(11):1520-34. PMC: 4641504. DOI: 10.15252/embr.201540437. View

16.

Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W . The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One. 2013; 8(10):e77293. PMC: 3796503. DOI: 10.1371/journal.pone.0077293. View

17.

Gao H, Song X, Kang T, Yan B, Feng L, Gao L . Long noncoding RNA functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017; 10:205-216. PMC: 5221653. DOI: 10.2147/OTT.S116178. View

18.

Modok S, Mellor H, Callaghan R . Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006; 6(4):350-4. DOI: 10.1016/j.coph.2006.01.009. View

19.

Sharom F . ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2007; 9(1):105-27. DOI: 10.2217/14622416.9.1.105. View

20.

Abbasifarid E, Sajjadi-Jazi S, Beheshtian M, Samimi H, Larijani B, Haghpanah V . The Role of ATP-Binding Cassette Transporters in the Chemoresistance of Anaplastic Thyroid Cancer: A Systematic Review. Endocrinology. 2019; 160(8):2015-2023. DOI: 10.1210/en.2019-00241. View